3-MeO-PCE acts principally as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole.”
3-MeO-PCE has Ki values of 61 nM for the NMDA receptor, 743 nM for the dopamine transporter, 2097 nM for the histamine H2 receptor, 964 nM for the Alpha-2A adrenergic receptor, 115 nM for the serotonin transporter, 4519 nM for the σ1 receptor and 525 nM for the σ2 receptor.
3-MeO-PCE can be said to share extremely similar properties to that of 3-MeO-PCP but with a potentially higher risk of inducing states of mania, delusions and potential psychosis due to the greater degree of euphoric stimulation and the compulsive redosing it can lead to. However, the effects are reported to largely converge with those of 3-MeO-PCP after a certain dose-point, when the dissociating effects come to dominate.
It is also often reported to be significantly more stimulating and less sedating than other dissociatives such as ketamine or MXE while more comfortable than O-PCE, MXP, diphenidine and other noradrenaline reuptake inhibiting dissociative compounds which suggests that it may have a higher affinity for dopamine or serotonin.
The toxicity and long-term health effects of recreational 3-MeO-toxic dosage is unknown. This is because 3-MeO-PCE has very little history of human usage.
3-MeO-PCE has been reported to cause psychosis, delusions, and mania at a significantly higher rate than other dissociatives such as ketamine, diphenidine, or MXE. There are a large number of experience reports online which describe states of "psychotic delirium, amnesia, mania, and other serious consequences" after abusing the substance.
It is strongly recommended that one use extreme caution and harm reduction practices when using this substance.
- Users should avoid using the substance multiple days in a row or becoming addicted to it as this increases the risk of severe adverse effects.
- The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
- Users should start with extremely low doses and work their way up as slowly as possible. Volumetric liquid dosing should preferably be used due to the substance's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
- Compulsive redosing before one has fully sobered up is not recommended and can result in too high of a dose.
Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially stimulants, psychedelics, or other dissociatives like MXE. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.
The chronic use of 3-MeO-highly addictive with a high potential for adverse side effects such as psychosis. In comparison to other dissociatives, 3-MeO-PCE has been reported to be more habit-forming than MXE, diphenidine, ephenidine, and ketamine. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.
Tolerance to many of the effects of 3-MeO-with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that,3 - 71 - 2 weeks to be back at baseline (in the absence of further consumption). 3-MeO-PCE presents cross-tolerance with Cross-all dissociatives, meaning that after the use of 3-MeO-PCE, all dissociatives will have a reduced effect.
Regarding its long-term health effects when used repeatedly and over excessive periods, 3-MeO-PCE seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is because 3-MeO-PCE is far more potent than ketamine, so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become severe and can be described as:
- Urinary frequency** - Urinary frequency is the need to empty the bladder every few minutes.
- Urinary urgency** - This can be described as a sudden, compelling need to urinate.
- Urinary pressure** - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
- Pelvic and bladder pain** - Pain can develop suddenly and severely, especially since the bladder fills with urine.
- Hematuria** - Hematuria is visible blood in the urine.
- Incontinence** - This is the leakage of urine.
All of these, however, can easily be avoided by simply not using 3-MeO-PCE on a daily or even weekly basis and consciously limiting one's usage of the substance.
Psychedelics** - This combination is not advised because 3-MeO-PCE has been reported to cause extreme psychological disturbances such as psychosis and mania at a significantly higher rate than other dissociatives.
Czech Republic:** 6-APB is a Schedule I (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of Nařízení vlády č. 463/2013 Sb.)
Germany:** 3-MeO-PCE is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland:** 3-MeO-PCE is a controlled substance specifically named under Verzeichnis E.
Turkey:** 3-MeO-PCE is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - 3-MeO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 1-phenylcyclohexylamine substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
Responsible use
Volumetric dosing
Research chemical
Dissociatives
Arylcyclohexylamines
3-MeO-PCP
PCP
3-MeO-PCE (Wikipedia)
3-MeO-PCE (Isomer Design)
3-MeO-PCE (Bluelight)
Interview with a Ketamine Chemist (VICE)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
a
3-MeO-PCE can be administered via insufflated, oral. The route of administration can influence both the onset and intensity of frame rate suppression.
